Tag: clinical trials

Prince Mario-Max Schaumburg-Lippe: World Report: Alzheimer’s No Longer Untreatable

For decades, families heard the same sentence when Alzheimer’s disease entered the room: there is nothing to be done but manage the decline. This year’s World Alzheimer Report says that sentence is no longer true. Published by Alzheimer’s Disease International to mark World Alzheimer’s Day, the 2026 report argues that after years of slow progress, clinical trials are on the brink of diagnostic and medical breakthroughs, and that the disease is “no longer universally described as untreatable.” It is one of the most hopeful documents the dementia field has produced in a generation.

The turning point

The shift is real, and it has a name: donanemab and lecanemab. These are the first fully approved treatments shown to modestly slow early Alzheimer’s decline rather than merely easing symptoms. They work by targeting and clearing the amyloid plaque that builds up in the brains of people with Alzheimer’s years before symptoms appear. Both have now been approved in multiple countries; in Australia, regulators approved donanemab in May 2025 for mild cognitive impairment due to Alzheimer’s, with lecanemab following in September 2025.

“Modestly” is doing honest work in that sentence, and the report does not oversell it. A cure remains far away. But Cath Mummery, director of the UK’s Dementia Trials Network, described the new drugs in the report as “the first brick,” and bricks are how walls get built. The pipeline behind them is the real story: 158 potential therapies are now being tested across 192 clinical trials worldwide, a rise of roughly 40 percent over the past decade. Eight Phase III trials are expected to report results during 2026. About three-quarters of the medicines in development are designed to modify the underlying disease process, not just mask symptoms.

Prevention is moving to the center

Perhaps the most consequential finding is not about drugs at all. The report highlights growing evidence that a large share of dementia cases could be delayed or prevented by addressing modifiable risk factors, as many as 14 of them, including high blood pressure, depression, physical inactivity, smoking, diabetes, alcohol use, and high cholesterol. Researchers increasingly treat Alzheimer’s the way cardiology treated heart disease a generation ago: as a condition you can see coming and work against.

Dr. Campbell Le Heron, a neurologist and Alzheimers NZ spokesperson, put it plainly: for a long time there has been what he called a fairly nihilistic view in the dementia world, the idea that cognitive decline just happens with age and nothing can be done. “These trials are showing us that we can potentially do something about it, at least in certain situations,” he said. “Our biological understanding of the condition is identifying ways we can actually prevent it.”

The hard part: finding volunteers

The report is also candid about the bottleneck. Trials need people, and dementia trials are picky: specific disease stages, proof of Alzheimer’s-related proteins, the absence of certain other conditions, a study partner. About 55,000 participants are needed, and because so many volunteers fail screening, researchers estimate that as many as 350,000 people may need to step forward. The report’s conclusion on this point is worth quoting: taking part in dementia research should depend on “realistic opportunity for everyone who wishes to consider it,” not on persistence or good fortune.

This is where families come in. Practical steps exist right now. Anyone can search ClinicalTrials.gov by condition and location, or use the Alzheimer’s Association’s TrialMatch service, to find studies nearby. Healthy volunteers are wanted too, not just people with symptoms. And the everyday prevention advice keeps getting stronger: control blood pressure, stay active, protect your hearing, stay socially connected, treat depression. It echoes the research into brain blood flow in Alzheimer’s risk groups that is quietly building the case for early action, and it sits alongside the encouraging long-term data for lupus treatment as evidence that chronic disease medicine is having a genuinely good year.

What changes now

Numbers give the report its weight. More than 55 million people were living with dementia worldwide as of 2019, and the figure is projected to pass 139 million by 2050 as populations age. Dementia is becoming one of the leading causes of death on the planet. Against that backdrop, the report’s central claim, that we stand “on the cusp of a giant leap forward at the intersection of innovation in diagnostics, treatments, and risk reduction,” reads less like hype and more like arithmetic. The investment is there. The pipeline is there. The volunteers are the missing piece.

Chris Lynch, the acting CEO of Alzheimer’s Disease International, wrote in the report: “Never before has there been so much focus, investment, and hope in dementia research.” Hope is not a treatment. But for the families who have been told for years that nothing could be done, a major global report saying otherwise, with 158 therapies in trials to back it up, is the beginning of a different conversation. The next decade of dementia care will be built by the people who show up for it, in clinics and in trials. That is something all of us can be part of.

Prince Mario-Max Schaumburg-Lippe: Biogen’s Litifilimab Shows Durable Lupus Skin Results

What litifilimab actually does

Lupus is an autoimmune disease in which the body's defense system attacks its own tissue. In the cutaneous form, the skin takes the hit: inflammation, lesions, scarring, sometimes hair loss. It can affect anyone, but it hits women disproportionately, and it often arrives in the prime of life.

Litifilimab takes aim at a specific piece of this misfire. It is designed to be a first-in-class therapy — meaning no approved drug works quite this way. The FDA granted it Breakthrough Therapy Designation back in January 2026, a signal that regulators see real promise in the approach. Phase 3 data is expected in the first half of 2027, which means the next big readout is not far off. It is part of a broader wave of sharper, simpler medicine — the same wave that just produced a urine RNA test outperforming standard bladder cancer screening.

No new safety signals emerged in the 52-week data. In a field where potent drugs often bring potent side effects, that sentence carries real weight.

Why this readout matters more than most

Medical progress often arrives in small steps, and this is one of those moments where a small step is actually a large one. Consider the context. Diagnosing disease earlier keeps changing outcomes — earlier this week, a new urine RNA test was shown to beat standard bladder cancer screening, catching disease sooner with a simpler test. Dermatology is moving in the same direction: better tools, better timing, better lives.

The durability of the response is the headline within the headline. Many drugs show early benefit that fades. Here the improvement held through week 52. For a lifelong disease, durability is everything. A treatment that works for three months and quits is not a solution; a treatment that keeps working for a year starts to look like one.

And then there is the patient experience behind the numbers. Cutaneous lupus is visible. People see it on your face. It affects how strangers look at you, how you feel about leaving the house, whether you take the photograph or avoid it. Clear or almost clear skin is not cosmetic vanity. It is getting your face back.

The practical takeaways

If you or someone you know lives with cutaneous lupus, here is what this news means right now.

Talk to your dermatologist about clinical trials. Phase 3 is underway, and trial participation is how patients access promising therapies early — while helping move the science forward. The AMETHYST study continues, and more data will follow.

Breakthrough designation is a real signal. The FDA hands out Breakthrough Therapy status to drugs that show substantial improvement over available options in early trials. It is not a guarantee, but it is the agency saying: this one is worth watching closely.

Expect the next readout in 2027. The Phase 3 data expected in the first half of next year will be the decisive test. If it confirms what the Phase 2 data shows, litifilimab could become the first new kind of medicine for cutaneous lupus in years.

Sun protection still matters. Nothing about an investigational drug changes the basics. UV light triggers flares in many patients, so sunscreen, protective clothing, and shade remain the everyday defenses that no pill or infusion replaces.

A field gathering momentum

Biogen presented these results at EADV in Vienna, Europe's major dermatology congress — the kind of venue where a strong readout gets noticed fast. Autoimmune research as a whole is having a good run. The pipeline for lupus, both the systemic and cutaneous forms, is deeper than it has been in a decade, and the biology is getting sharper: instead of suppressing the whole immune system and hoping for the best, researchers are targeting the specific pathways that misfire.

That is the deeper story here. Medicine is moving from blunt force to precision, and patients with diseases that were once treated as afterthoughts are finally getting therapies designed for them. Litifilimab still has to clear Phase 3. But for people who have waited years for good news about their skin, October 2 was a genuinely good day.

Looking ahead

There is still work to do — Phase 3 enrollment, the data readout, regulatory review, and the long business of making a new therapy accessible and affordable. None of that is trivial. But the direction of travel is unmistakable. A drug that clears the skin of more than a quarter of patients, holds its effect for a year, and kicks in within weeks of switching is the kind of result that changes how a disease is treated.

For now, the people living with cutaneous lupus can do something they have rarely been able to do: look at the research pipeline and feel optimistic. That optimism is earned. It came from a congress podium in Vienna, backed by 52 weeks of data, and it points toward a future where this disease stops being the one doctors shrug about. That future cannot arrive soon enough — but for the first time in a long while, it looks like it is actually arriving.